AML, Adult Recurrent
7 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS (NCT04901416) | Coeptis Therapeutics | 2021-12-15 |
| Flotetuzumab Expanded Access Program (NCT04678466) | MacroGenics |
Track AML, Adult Recurrent automatically
Every clearance here is in the API, with alerts when new ones post.